Depreciation & Amortization
The latest quarterly d&a is $69.03 Million with a quarter-over-quarter change of +10.75%. Depreciation and Amortization (D&A) is a non-cash expense that allocates the cost of tangible and intangible assets over their useful lives.
RMD D&A
Reported quarterly depreciation and amortization; no daily interpolation.
Current D&A
$69.03M
$69.03 Million
Quarter-over-Quarter Change
+10.75%
vs. $62.33M prior quarter
Historical Data
96
Quarters of data available
Quarterly D&A History
| Period | D&A | QoQ Change | % Change |
|---|---|---|---|
| Q3 2026 | $69.03M | +$6.70M | +10.75% |
| Q2 2025 | $62.33M | +$4.66M | +8.08% |
| Q1 2025 | $57.67M | $-16.62M | -22.37% |
| Q4 2025 | $74.29M | +$22.38M | +43.11% |
| Q3 2025 | $51.91M | $-3.99M | -7.14% |
| Q2 2024 | $55.90M | +$2.19M | +4.08% |
| Q1 2024 | $53.71M | $-1.04M | -1.91% |
| Q4 2024 | $54.75M | +$112,000 | +0.20% |
| Q3 2024 | $54.64M | +$1.27M | +2.38% |
| Q2 2023 | $53.37M | $-72,000 | -0.13% |
| Q1 2023 | $53.44M | $-1.76M | -3.18% |
| Q4 2023 | $55.20M | +$2.41M | +4.57% |
| Q3 2023 | $52.79M | +$7.25M | +15.92% |
| Q2 2022 | $45.54M | +$1.50M | +3.42% |
| Q1 2022 | $44.03M | $-973,000 | -2.16% |
| Q4 2022 | $45.01M | $-6.60M | -12.79% |
| Q3 2022 | $51.61M | +$2.00M | +4.04% |
| Q2 2021 | $49.61M | +$1.99M | +4.17% |
| Q1 2021 | $47.62M | +$1.94M | +4.25% |
| Q4 2021 | $45.68M | $-2.20M | -4.60% |
| Q3 2021 | $47.88M | $-187,000 | -0.39% |
| Q2 2020 | $48.07M | $-1.82M | -3.65% |
| Q1 2020 | $49.89M | +$4.38M | +9.62% |
| Q4 2020 | $45.51M | $-957,000 | -2.06% |
| Q3 2020 | $46.47M | +$982,000 | +2.16% |
| Q2 2019 | $45.48M | +$1.57M | +3.57% |
| Q1 2019 | $43.92M | +$1.32M | +3.11% |
| Q4 2019 | $42.59M | +$842,000 | +2.02% |
| Q3 2019 | $41.75M | +$5.72M | +15.88% |
| Q2 2018 | $36.03M | +$5.61M | +18.42% |
| Q1 2018 | $30.42M | $-1.28M | -4.04% |
| Q4 2018 | $31.70M | +$2.39M | +8.16% |
| Q3 2018 | $29.31M | $-63,000 | -0.21% |
| Q2 2017 | $29.37M | $-197,000 | -0.67% |
| Q1 2017 | $29.57M | +$1.40M | +4.98% |
| Q4 2017 | $28.17M | $-317,000 | -1.11% |
| Q3 2017 | $28.48M | +$756,000 | +2.73% |
| Q2 2016 | $27.73M | $-46,000 | -0.17% |
| Q1 2016 | $27.77M | +$753,000 | +2.79% |
| Q4 2016 | $27.02M | +$7.12M | +35.74% |
| Q3 2016 | $19.91M | $-1.61M | -7.48% |
| Q2 2015 | $21.52M | +$3.11M | +16.92% |
| Q1 2015 | $18.40M | +$657,000 | +3.70% |
| Q4 2015 | $17.75M | $-113,000 | -0.63% |
| Q3 2015 | $17.86M | $-1.01M | -5.35% |
| Q2 2014 | $18.87M | +$287,000 | +1.54% |
| Q1 2014 | $18.58M | $-1.24M | -6.26% |
| Q4 2014 | $19.82M | +$2.64M | +15.38% |
| Q3 2014 | $17.18M | $-1.40M | -7.53% |
| Q2 2013 | $18.58M | +$710,000 | +3.97% |
| Q1 2013 | $17.87M | $-1.79M | -9.10% |
| Q4 2013 | $19.66M | $-1.01M | -4.91% |
| Q3 2013 | $20.67M | +$1.38M | +7.14% |
| Q2 2012 | $19.30M | +$647,000 | +3.47% |
| Q1 2012 | $18.65M | $-107.23M | -85.18% |
| Q4 2012 | $125.88M | +$169.72M | +387.08% |
| Q3 2012 | $-43.85M | +$58.59M | +57.20% |
| Q2 2011 | $-102.44M | $-122.85M | -601.92% |
| Q1 2011 | $20.41M | +$53.40M | +161.87% |
| Q4 2011 | $-32.99M | $-32.99M | — |
| Q3 2011 | $0 | $-17.35M | -100.00% |
| Q2 2010 | $17.35M | +$1.70M | +10.89% |
| Q1 2010 | $15.64M | +$169,000 | +1.09% |
| Q4 2010 | $15.47M | $-643,000 | -3.99% |
| Q3 2010 | $16.12M | +$516,000 | +3.31% |
| Q2 2009 | $15.60M | +$1.23M | +8.53% |
| Q1 2009 | $14.37M | $-524,000 | -3.52% |
| Q4 2009 | $14.90M | +$1.96M | +15.17% |
| Q3 2009 | $12.94M | +$1.17M | +9.90% |
| Q2 2008 | $11.77M | $-2.59M | -18.02% |
| Q1 2008 | $14.36M | $-2.19M | -13.25% |
| Q4 2008 | $16.55M | +$1.81M | +12.32% |
| Q3 2008 | $14.74M | +$928,000 | +6.72% |
| Q2 2007 | $13.81M | $-582,000 | -4.04% |
| Q1 2007 | $14.39M | +$1.25M | +9.54% |
| Q4 2007 | $13.14M | +$879,000 | +7.17% |
| Q3 2007 | $12.26M | +$219,000 | +1.82% |
| Q2 2006 | $12.04M | +$1.33M | +12.44% |
| Q1 2006 | $10.71M | $-384,000 | -3.46% |
| Q4 2006 | $11.09M | +$271,000 | +2.50% |
| Q3 2006 | $10.82M | +$949,000 | +9.61% |
| Q2 2005 | $9.87M | +$34,000 | +0.35% |
| Q1 2005 | $9.84M | +$853,000 | +9.49% |
| Q4 2005 | $8.98M | +$1.50M | +20.01% |
| Q3 2005 | $7.49M | +$656,000 | +9.60% |
| Q2 2004 | $6.83M | +$1.00M | +17.23% |
| Q1 2004 | $5.83M | +$1.33M | +29.61% |
| Q4 2004 | $4.50M | $-250,000 | -5.27% |
| Q3 2004 | $4.75M | +$240,000 | +5.33% |
| Q2 2003 | $4.50M | +$383,000 | +9.29% |
| Q1 2003 | $4.12M | +$1.13M | +37.72% |
| Q4 2003 | $2.99M | $-395,000 | -11.66% |
| Q3 2003 | $3.39M | +$159,000 | +4.92% |
| Q2 2002 | $3.23M | +$256,000 | +8.61% |
| Q1 2002 | $2.97M | +$962,000 | +47.84% |
| Q4 2002 | $2.01M | — | — |
Related Metrics
About ResMed Inc.
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Michael J. Farrell